About Immunovant Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://immunovant.com/
Frequently Asked Questions
What is the 52-week range for IMVT?
The 52-week high is $45.42 and the 52-week low is $15.95.
What is the P/E ratio for IMVT?
The P/E ratio data is currently unavailable.
What is the dividend yield for IMVT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -69.59%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.93.
Analyst Recommendation Trends
Wall Street analyst consensus for IMVT over the last few months:
Latest IMVT News
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
Immunovant recently reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, where the drug did not achieve statistical significance on the primary CLASI-A endpoint at Week 12, leading the company to halt development for this indication. Despite observing numerical trends favoring IMVT-1402 and better responses in patients with deeper IgG reductions, Immunovant concluded that the combination of these data and a competitive treatment...
Immunovant (IMVT) Just Gave Investors Something To Think About
Immunovant (IMVT) just told the market that its proof-of-concept Phase 2b trial for IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the program in this indication is being discontinued. The mixed trial outcome lands at a sensitive moment for Immunovant. The share price is US$33.49 after a 1-day share price return of 0.57%, yet the 7-day share price return is down 9.92% and the 30-day share price return is down 18.71%. This hints that recent traders have been...
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower. The company reported that its Phase 2b proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve the primary endpoint. The study failed to show a statistically significant difference […]
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
Roivant reports top-line data from IMVT-1402 CLE trial
This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
Immunovant halts development of its lead drug candidate, imeroprubart, in skin lupus following a trial miss.
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
Immunovant (NASDAQ:IMVT) shares fell 6% on Monday after the company reported that a proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus did not meet its primary endpoint. The trial did not achieve statistical significance on its primary endpoint, which measured the percentage change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12.
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140
Immunovant Ends Autoimmune Skin Disorder Program
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and
Immunovant Q1 2027 Earnings Call: Complete Transcript
On Thursday, Immunovant (NASDAQ:IMVT) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access
Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value
Immunovant has delivered very strong long term returns, and that kind of share price journey naturally raises the question of whether the current valuation still lines up with the company’s book value. With fresh attention on its autoimmune drug programs, investors are asking how much of that story is already embedded in the balance sheet metrics. Over the past 5 years, Immunovant has returned 337.4%, which puts a lot of weight on whether the underlying equity on its balance sheet can...
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?
Immunovant (IMVT) has drawn fresh attention after recent trading left the stock around $37.36, with short term moves weaker but a strong total return profile over the past year and beyond. Recent trading tells a mixed story for Immunovant. Short term share price momentum has faded, with the stock down 4.8% over the past week and 10.7% over the past month. However, the 90 day share price return of 11.2% and 1 year total shareholder return of 140.6% show that longer term holders have still seen...
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants
Roivant Sciences outlook: LISRAYA approval strengthens revenue, while brepocitinib and mosliciguat could expand immunology/pulmonary franchises. Click for more on ROIV stock.
Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline Innovation
New Spherix Global Insights research finds rheumatologists estimate 16% of rheumatoid arthritis patients are refractory to treatment, underscoring continued demand for differentiated therapies despite an increasingly crowded market.Exton, PA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- As the Rheumatoid Arthritis (RA) treatment landscape becomes increasingly competitive, rheumatologists are looking to the pipeline for therapies that can offer more than incremental differentiation. New research from Spher
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-23 | Van Tuyl Christopher | -2,846 | $36.36 | $103,481 |
| 2026-08-28 | Pande Atul | -1,500 | - | - |
| 2026-08-28 | Pande Atul | -1,500 | $43.27 | $64,905 |
| 2026-08-28 | Pande Atul | +1,500 | $8.43 | $12,645 |
| 2026-08-20 | Gloria Melanie | -3,056 | $44.16 | $134,953 |
| 2026-07-24 | Pande Atul | -1,500 | - | - |
| 2026-07-24 | Pande Atul | -1,500 | $39.8 | $59,700 |
| 2026-07-24 | Pande Atul | +1,500 | $8.43 | $12,645 |
| 2026-07-23 | Stout Jay S | -2,857 | $38.69 | $110,537 |
| 2026-07-23 | Girao Tiago | -6,798 | $38.69 | $263,015 |
| 2026-07-08 | Gloria Melanie | -106 | $39.99 | $4,239 |
| 2026-07-08 | Gloria Melanie | -1,930 | $39.53 | $76,293 |
| 2026-07-08 | Van Tuyl Christopher | -63 | $39.99 | $2,519 |
| 2026-07-08 | Van Tuyl Christopher | -1,143 | $39.53 | $45,183 |
| 2026-07-08 | Stout Jay S | -77 | $39.99 | $3,079 |
| 2026-07-08 | Stout Jay S | -1,399 | $39.53 | $55,302 |
| 2026-07-08 | Stout Jay S | -105 | $39.99 | $4,199 |
| 2026-07-08 | Stout Jay S | -1,906 | $39.53 | $75,344 |
| 2026-07-02 | Venker Eric | -3,092 | $38.48 | $118,980 |
| 2026-07-01 | Venker Eric | -92,188 | - | - |
| 2026-07-01 | Venker Eric | -86,629 | $38.14 | $3,304,030 |
| 2026-07-01 | Venker Eric | +92,188 | $14.46 | $1,333,038 |
| 2026-06-26 | Gloria Melanie | -2,966 | $38.95 | $115,526 |
| 2026-06-26 | Gloria Melanie | -14,748 | $38.18 | $563,079 |
| 2026-06-26 | Van Tuyl Christopher | -17,824 | - | - |
| 2026-06-26 | Van Tuyl Christopher | -2,842 | $38.96 | $110,724 |
| 2026-06-26 | Van Tuyl Christopher | -14,982 | $38.19 | $572,163 |
| 2026-06-26 | Van Tuyl Christopher | +17,824 | $15.2 | $270,925 |
| 2026-06-26 | Stout Jay S | -6,723 | $38.94 | $261,794 |
| 2026-06-26 | Stout Jay S | -33,277 | $38.18 | $1,270,516 |
| 2026-06-26 | Pande Atul | -1,500 | - | - |
| 2026-06-26 | Pande Atul | -1,500 | $38.01 | $57,015 |
| 2026-06-26 | Pande Atul | +1,500 | $8.43 | $12,645 |
| 2026-06-26 | Girao Tiago | -10,000 | - | - |
| 2026-06-26 | Girao Tiago | -10,000 | $38.46 | $384,600 |
| 2026-06-26 | Girao Tiago | +10,000 | $15.9 | $159,000 |
| 2026-06-18 | Van Tuyl Christopher | -2,634 | $35.39 | $93,217 |
| 2026-06-15 | Pande Atul | -1,500 | - | - |
| 2026-06-15 | Pande Atul | -1,500 | $34.02 | $51,030 |
| 2026-06-15 | Pande Atul | +1,500 | $8.43 | $12,645 |
| 2026-05-28 | Fromkin Andrew J. | -16,260 | - | - |
| 2026-05-28 | Fromkin Andrew J. | -77,181 | - | - |
| 2026-05-28 | Fromkin Andrew J. | -71,492 | - | - |
| 2026-05-28 | Fromkin Andrew J. | -31,668 | - | - |
| 2026-05-28 | Fromkin Andrew J. | -210,468 | $33.56 | $7,063,306 |
| 2026-05-28 | Fromkin Andrew J. | -11,483 | $32.64 | $374,805 |
| 2026-05-28 | Fromkin Andrew J. | +16,260 | $14.7 | $239,022 |
| 2026-05-28 | Fromkin Andrew J. | +77,181 | $8.43 | $650,636 |
| 2026-05-28 | Fromkin Andrew J. | +71,492 | $7.94 | $567,646 |
| 2026-05-28 | Fromkin Andrew J. | +31,668 | $4.99 | $158,023 |
| 2026-05-20 | Pande Atul | -6,000 | - | - |
| 2026-05-20 | Pande Atul | -6,000 | $32 | $192,000 |
| 2026-05-20 | Pande Atul | +6,000 | $8.43 | $50,580 |
| 2026-05-20 | Gloria Melanie | -1,698 | $32.95 | $55,949 |
| 2026-05-20 | Gloria Melanie | -1,168 | $32.15 | $37,551 |
| 2026-05-20 | Gloria Melanie | -249 | $30.41 | $7,572 |
| 2026-05-01 | Susman Robert Graham | -2,502 | $27.17 | $67,979 |
| 2026-04-23 | Stout Jay S | -2,754 | $29.62 | $81,573 |
| 2026-04-23 | Girao Tiago | -25,760 | $29.62 | $763,011 |
| 2026-04-08 | Gloria Melanie | -8,722 | $24.83 | $216,567 |
| 2026-04-08 | Van Tuyl Christopher | -5,165 | $24.83 | $128,247 |
| 2026-04-08 | Stout Jay S | -1,518 | $24.83 | $37,692 |
| 2026-04-08 | Stout Jay S | -8,614 | $24.83 | $213,886 |
| 2026-04-07 | Susman Robert Graham | +7,061 | - | - |
| 2026-04-07 | Susman Robert Graham | +13,880 | - | - |
| 2026-04-07 | Gloria Melanie | +121,063 | - | - |
| 2026-04-07 | Gloria Melanie | +83,671 | - | - |
| 2026-04-07 | Van Tuyl Christopher | +59,820 | - | - |
| 2026-04-07 | Van Tuyl Christopher | +41,343 | - | - |
| 2026-04-07 | Venker Eric | +336,043 | - | - |
| 2026-04-07 | Venker Eric | +232,252 | - | - |
| 2026-04-07 | Hughes Douglas J. | +7,061 | - | - |
| 2026-04-07 | Hughes Douglas J. | +13,880 | - | - |
| 2026-04-07 | Stout Jay S | +96,851 | - | - |
| 2026-04-07 | Stout Jay S | +66,937 | - | - |
| 2026-04-07 | Bauer Jake | +7,061 | - | - |
| 2026-04-07 | Bauer Jake | +13,880 | - | - |
| 2026-04-07 | Torti Frank | +88,325 | - | - |
| 2026-04-07 | Torti Frank | +174,189 | - | - |
| 2026-04-07 | Pande Atul | +7,061 | - | - |
| 2026-04-07 | Pande Atul | +13,880 | - | - |
| 2026-04-07 | Girao Tiago | +94,002 | - | - |
| 2026-04-07 | Girao Tiago | +64,968 | - | - |
| 2026-04-07 | Fromkin Andrew J. | +7,061 | - | - |
| 2026-04-07 | Fromkin Andrew J. | +13,880 | - | - |
| 2026-04-02 | Venker Eric | -1,409 | $24.6 | $34,661 |
| 2026-04-02 | Venker Eric | -12,820 | $24.04 | $308,193 |
| 2026-04-01 | Venker Eric | -368,750 | - | - |
| 2026-04-01 | Venker Eric | -334,960 | $25.1 | $8,407,496 |
| 2026-04-01 | Venker Eric | +368,750 | $14.46 | $5,332,125 |
| 2026-03-18 | Van Tuyl Christopher | -2,877 | $24.97 | $71,839 |
| 2026-02-25 | Gloria Melanie | -942 | $28.9 | $27,224 |
| 2026-02-25 | Gloria Melanie | -859 | $28.16 | $24,189 |
| 2026-02-25 | Gloria Melanie | -1,437 | $26.98 | $38,770 |
| 2026-01-21 | Stout Jay S | -1,977 | $26.03 | $51,461 |
| 2026-01-07 | Stout Jay S | -55 | $26.92 | $1,481 |
| 2026-01-07 | Stout Jay S | -1,148 | $26.51 | $30,433 |
| 2025-12-18 | Van Tuyl Christopher | -2,284 | $27.38 | $62,536 |
| 2025-12-18 | Van Tuyl Christopher | -8,529 | $26.78 | $228,407 |
| 2025-12-12 | Roivant Sciences Ltd. | +16,666,666 | $21 | $349,999,986 |
| 2025-12-01 | Hughes Douglas J. | -1,909 | $23.96 | $45,740 |
| 2025-12-01 | Hughes Douglas J. | -13,091 | $23.14 | $302,926 |
| 2025-12-01 | Fromkin Andrew J. | -2,898 | $23.95 | $69,407 |
| 2025-12-01 | Fromkin Andrew J. | -19,351 | $23.14 | $447,782 |
| 2025-11-20 | Gloria Melanie | -2,375 | $23.97 | $56,929 |
| 2025-11-20 | Gloria Melanie | -10,251 | $23.54 | $241,309 |
| 2025-10-22 | Geffner Michael | -2,595 | $19.03 | $49,383 |
| 2025-10-22 | Stout Jay S | -2,520 | $19.03 | $47,956 |
| 2025-10-08 | Geffner Michael | -1,272 | $16.3 | $20,734 |
| 2025-10-08 | Stout Jay S | -1,585 | $16.3 | $25,836 |